Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data ...

MALVERN, Pa.--(BUSINESS WIRE)--Parkinson’s disease is the second most prevalent neurodegenerative disease and presents a global health challenge. About 90,000 people are diagnosed in the US every year ...

Tavapadon may delay levodopa use in early Parkinson’s and help stabilize dosing in the later stages of the disease, with most patients avoiding initiation or dose increases.

Researchers are making strides toward more personalized Parkinson’s disease care, with a new study identifying distinct genetic subtypes and an experimental drug showing it can safely reduce levels of ...

A government expert panel agreed on May 13 to cover the world’s first iPS cell-based medicine for the treatment of ...

How well our brain functions depends heavily on the performance of our nerve cells. That is why they are regularly checked for their proper function -- defective cell components are marked, disposed ...

A Japanese health ministry panel on Wednesday approved public health insurance coverage for a regenerative medicine product ...

Bacteria and plastic waste each can pose health and environmental issues. But new research shows that when used together, they can have a positive health impact by creating a frontline medication for ...